Form D · Other
Siren Biotechnology, Inc.
San Francisco, CA · CIK 0002020584
Offering snapshot reported Apr 22, 2024 · SEC filing
- Reported sold
- $19.6M Offering amount: $32.4M
- Investors reported
- 57 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 8, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 22, 2024 | Initial | $19,611,194 | No comparison | 57 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-511190
Series A-1 Preferred Stock, Series A-2 Preferred Stock and the common stock issuable upon conversion thereof.
Source: Form D, filed Apr 22, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brad Allen | Director |
| Nicole Paulk | Director, Executive |
| Sharon Tetlow | Director |
Issuer details
Industry: Other (See others in industry)
Address:
455 Mission Bay Boulevard South
San Francisco, CA, 94158
San Francisco, CA, 94158